SPL026 With or Without SSRIs in Participants With MDD
NCT05553691 · Small Pharma Ltd
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Safety & tolerability: Adverse Events
Measured over Screening to End-of-Study Follow-up (Day 29)
Safety & tolerability: Lab biochemistry
Measured over Screening, Day -1 and Day 1
Safety & tolerability: Vital signs - Heart Rate
Measured over Screening to Day 2
Safety & tolerability: Vital signs - Blood pressure
Measured over Screening to Day 2
Safety & tolerability: Vital signs - Temperature
Measured over Screening to Day 2
Safety & tolerability: Electrocardiogram
Measured over Screening to Day 2
Safety & tolerability: Suicidal Ideation
Measured over Screening to End-of-Study Follow-up (Day 29)
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
2 study sites
| Facility | City | Region | Country |
|---|---|---|---|
| Mac Clinical Research | Manchester | Greater Manchester | United Kingdom |
| MAC Clinical Research | Liverpool | Prescot | United Kingdom |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT05553691 on ClinicalTrials.gov →
Last updated in the registry 2024-06-14. Registry records change; this page reflects the data build of 2026-08-25.
Related
Where this trial sits
Substance
Indication